Gordon Muirhead to lead the 1nhaler Board of Directors

1nhaler is pleased to announce the appointment of Gordon Muirhead as our new Chair to the 1nhaler Board of Directors.

Gordon replaces Jane Gaddum as Chair at a time when the company is moving forward with Harro Höfliger to upscale manufacturing plans in preparation for launch of its initial product, 1nhaler Salbutamol.

Gordon has been a strategic advisor to 1nhaler since its inception and a non-executive board member since 2023.  Gordon is working closely with our manufacturing partners, Harro Höfliger, to develop large-scale manufacturing plans for bringing our lead product, 1nhaler Salbutamol, to market during 2028.

Gordon’s experience leading the introduction of new products and establishing global manufacturing supply chain capabilities for GSK are critical to shaping this next phase in the development of our pop-up cardboard single-dose inhaler.

Our thanks and appreciation to Jane Gaddum for her hard work and support establishing strong governance over the past two years.